FDFThe CEO Who Raised Drug Prices 500% and Destroyed a $90B Company

Описание: The CEO Who Raised Drug Prices 500% and Destroyed a $90B Company

For a brief moment, Valeant Pharmaceuticals was one of Wall Street’s greatest success stories — a company valued at nearly $90 billion, praised for its “innovative” business model and relentless growth.
Then the prices exploded.
And the empire collapsed.

This documentary investigates how Valeant, under CEO Michael Pearson, built a pharmaceutical giant by acquiring old drugs, slashing research, and raising prices by 400%, 500%, and more — often on life-saving medications patients had no alternative but to buy.

What investors once celebrated as efficiency eventually revealed a fragile system built on debt, secrecy, and pricing power that couldn’t survive scrutiny.

Inside This Investigation
This film traces Valeant’s rise and fall step by step:

The Acquisition Machine
Rather than invent new drugs, Valeant bought existing ones — then dramatically raised prices to boost revenue and please shareholders.

R&D Replaced by Financial Engineering
Research budgets were cut while acquisitions and leverage expanded, turning innovation into accounting.

The Price Shock
Patients, doctors, and lawmakers began asking why decades-old medicines suddenly cost several times more overnight.

The Philidor Connection
A secretive specialty pharmacy, Philidor, emerged as a key distributor — later triggering allegations of deceptive practices, revenue manipulation, and conflicts of interest.

Investigations and Exposure
Congressional hearings, regulatory probes, and media investigations unraveled the story Wall Street had ignored.

The Collapse
As scrutiny intensified:

• Valeant’s stock imploded
• tens of billions in market value vanished
• executives resigned
• lawsuits followed
• creditors closed in

The company that symbolized pharmaceutical “innovation” became a warning about leverage, opacity, and unchecked pricing power.

Why This Case Matters
Valeant wasn’t just a corporate failure.

It exposed:
• how drug pricing incentives work
• how financial markets reward short-term gains
• how accountability gaps persist even after collapse
• how patients often pay the price long before investors do

Even after the downfall, many of the structural incentives that enabled extreme price hikes remained largely intact.

The Bigger Lesson
This documentary isn’t about one executive alone.
It’s about a system where:
• market power replaces innovation
• debt amplifies risk
• oversight arrives too late
• consequences rarely match the damage

Valeant didn’t just collapse — it revealed how easily healthcare can be turned into a financial extraction model.

Join the Investigation
If this documentary changed how you see drug pricing, corporate power, or Wall Street incentives, hit LIKE, SHARE, and SUBSCRIBE to Corruption Rewind, where we examine the systems behind corporate rise, collapse, and accountability.

👇 Comment Below :
Do you think extreme drug price hikes are a failure of companies — or of regulation?

🔴 DISCLAIMER :

This video is for educational and informational purposes only. It is based on publicly reported investigations, court filings, congressional testimony, and investigative journalism related to Valeant Pharmaceuticals. Allegations are described as reported by authorities and media at the time. This content does not constitute medical, legal, or financial advice.


#CorruptionRewind
#Valeant
#ValeantPharmaceuticals
#ValeantCollapse
#MichaelPearson
#BauschHealth
#BigPharma
#PharmaScandal
#PharmaceuticalFraud
#PharmaceuticalFraudHistory
#DrugPrices
#DrugPriceHikes
#DrugPricingScandal
#DrugPriceGouging
#DrugPriceGougingExplained
#DrugPricingAccountability
#HealthcarePricing
#HealthcarePricingExplained
#HealthcareCorruption
#PatientRights
#MedicalDebt
#CorporateGreed
#CorporateGreedDocumentary
#CorporateCollapse
#CorporateCollapseDocumentary
#ValeantPhilidor
#Philidor
#AccountingFraud
#WallStreet
#WallStreetPharma
#WallStreetPharmaScandal
#FinancialScandal
#StockMarket
#BusinessDocumentary
#TrueCrimeFinance
#FinancialCrime
#SEC
#Congress
#BillAckman
#PershingSquare
#CitronResearch
#AndrewLeft
#ValeantCaseStudy
#PharmaceuticalIndustry
#PharmaceuticalIndustryFailure